5G1.1 monoclonal antibody C5 complement inhibitor: began a double-blind, placebo-controlled phase I/II trial

Alexion Pharmaceuticals Inc. (ALXN), New Haven, Conn. Product: 5G1.1 monoclonal antibody C5 complement inhibitor Indication: Treat systemic lupus erythematosus Status: ALXN began a double-blind, pla...